Drugs / tgDCC-E1A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00102622 | Dec 2004 → Jul 2012 | ovarian cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tgDCC-E1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00102622 ↗ |
| Route | Other | “intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m\^2 weekly” NCT00102622 ↗ |